Vyant Bio Inc Revenue Growth Rates (VYNT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vyant Bio Inc   (NASDAQ: VYNT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

VYNT's Revenue Growth by Quarter and Year

Vyant Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VYNT Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 0.05
3rd Quarter September 0.15
2nd Quarter June 0.17
1st Quarter March 0.30
FY 0.67

VYNTs Annual Revenue
Vyant Bio Inc 's Revenue in the fiscal year 2022 $ 0.67 millions
Vyant Bio Inc 's Revenue in the fiscal year 2021 $ 1.15 millions
Vyant Bio Inc 's Revenue in the fiscal year 2020 $ 5.75 millions
Vyant Bio Inc 's Revenue in the fiscal year 2019 $ 7.31 millions
Vyant Bio Inc 's Revenue in the fiscal year 2018 $ 27.47 millions




VYNT Revenue fourth quarter 2022 Y/Y Growth Comment
Vyant Bio Inc reported drop in Revenue in the fourth quarter 2022 by -87.22% to $ 0.05 millions, from the same quarter in 2021.
The fall in the fourth quarter 2022 Vyant Bio Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 9%.

Looking into fourth quarter 2022 results within Medical Laboratories industry 47 other companies have achieved higher Revenue growth. While Vyant Bio Inc ' s Revenue meltdown of -87.22% ranks overall at the positon no. 4711 in the fourth quarter 2022.


VYNT Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December -87.22 % -72.52 % -30.69 % -72.33 %
3rd Quarter September -90.07 % -3.82 % -24.15 % -65.15 %
2nd Quarter June -91.28 % 34.48 % -5.23 % -78.27 %
1st Quarter March 36.36 % -84.62 % -79.09 % -10.82 %
FY   -83.51 % -29.86 % -53.28 % -

Financial Statements
Vyant Bio Inc 's fourth quarter 2022 Revenue $ 0.05 millions VYNT's Income Statement
Vyant Bio Inc 's fourth quarter 2021 Revenue $ 0.36 millions Quarterly VYNT's Income Statement


VYNT Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December -69.33 % -76.16 % -16.56 % -8.7 %
3rd Quarter September -11.76 % -22.56 % 8.28 % 35.29 %
2nd Quarter June -43.33 % 786.36 % 1.4 % -77.63 %
1st Quarter March -16.67 % -83.21 % -24.34 % 0.15 %
FY (Year on Year)   -83.51 % -29.86 % -53.28 % -


Back to VYNT Growth rate Comparisons >> Back to VYNT Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #48
Healthcare Sector #730
Overall #4711

Revenue Y/Y Growth Statistics
High Average Low
205.54 % 9 % -91.53 %
(Jun 30 2021)   (Mar 31 2021)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #48
Healthcare Sector #730
Overall #4711
Revenue Y/Y Growth Statistics
High Average Low
205.54 % 9 % -91.53 %
(Jun 30 2021)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Vyant Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
777.03 % 21.11 % -83.07 %
(Jun 30 2021)  


VYNT's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Vyant Bio Inc disclosed fall in Revenue from the third quarter by -69.33% to $ 0.05 millions, from $ 0.15 millions achived in the previous reporting period.

But that's not important problem, as Vyant Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Vyant Bio Inc 's Revenue growth quarter on quarter, overall rank is 3619.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #37
Healthcare Sector #616
Overall #3619
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #37
Healthcare Sector #616
Overall #3619
Revenue Q/Q Growth Statistics
High Average Low
777.03 % 21.11 % -83.07 %
(Jun 30 2021)  


VYNT's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2022 Vyant Bio Inc disclosed fall in Revenue from the third quarter by -69.33% to $ 0.05 millions, from $ 0.15 millions achived in the previous reporting period.

But that's not important problem, as Vyant Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Vyant Bio Inc 's Revenue growth quarter on quarter, overall rank is 3619.


Vyant Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 0.67 $ 0.98 $ 2.33 $ 4.12 $ 4.04
Y / Y Revenue Growth (TTM) -83.49 % -80.34 % -53.76 % -9.48 % -29.84 %
Year on Year Revenue Growth Overall Ranking # 4114 # 108 # 0 # 3360 # 3592
Seqeuential Revenue Change (TTM) -32.04 % -58.01 % -43.29 % 2.01 % -19.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 4105 # 2602 # 0 # 971 # 3792


Cumulative Revenue growth Comment
Vyant Bio Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -83.49% year on year, at Dec 31 2022 compare to the -80.34% decrease at Sep 30 2022. If the Vyant Bio Inc 's fiscal year would end at Dec 31 2022, annual Revenue would be $1 millions.

In the Healthcare sector 602 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 108 to 4114.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 41
Healthcare Sector # 603
Overall # 4114

Revenue TTM Y/Y Growth Statistics
High Average Low
280.03 %
 6.78 %
-138.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 599
S&P 500 # 4105
Cumulative Revenue growth Comment
Vyant Bio Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -83.49% year on year, at Dec 31 2022 compare to the -80.34% decrease at Sep 30 2022. If the Vyant Bio Inc 's fiscal year would end at Dec 31 2022, annual Revenue would be $1 millions.

In the Healthcare sector 602 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 108 to 4114.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 41
Healthcare Sector # 603
Overall # 4114

Revenue TTM Y/Y Growth Statistics
High Average Low
280.03 %
6.78 %
-138.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 599
S&P 500 # 4105




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VYNT's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Vyant Bio Inc Revenue Growth Rates (VYNT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vyant Bio Inc (CIK 1349929).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-23-010255
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vyant Bio Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.